- Home
- PML vs KALV Comparison
PML vs KALV Comparison
Compare PML & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PML
- KALV
- Stock Information
- Founded
- PML 2002
- KALV N/A
- Country
- PML United States
- KALV United States
- Employees
- PML N/A
- KALV N/A
- Industry
- PML Investment Managers
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- PML Finance
- KALV Health Care
- Exchange
- PML Nasdaq
- KALV Nasdaq
- Market Cap
- PML 576.5M
- KALV 523.1M
- IPO Year
- PML N/A
- KALV N/A
- Fundamental
- Price
- PML $9.35
- KALV $11.36
- Analyst Decision
- PML
- KALV Strong Buy
- Analyst Count
- PML 0
- KALV 4
- Target Price
- PML N/A
- KALV $29.00
- AVG Volume (30 Days)
- PML 188.0K
- KALV 594.2K
- Earning Date
- PML 01-01-0001
- KALV 09-05-2024
- Dividend Yield
- PML 5.65%
- KALV N/A
- EPS Growth
- PML N/A
- KALV N/A
- EPS
- PML N/A
- KALV N/A
- Revenue
- PML N/A
- KALV N/A
- Revenue This Year
- PML N/A
- KALV N/A
- Revenue Next Year
- PML N/A
- KALV $250.03
- P/E Ratio
- PML N/A
- KALV N/A
- Revenue Growth
- PML N/A
- KALV N/A
- 52 Week Low
- PML $6.92
- KALV $7.21
- 52 Week High
- PML $9.46
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- PML 64.01
- KALV 49.59
- Support Level
- PML $9.14
- KALV $10.93
- Resistance Level
- PML $9.52
- KALV $11.98
- Average True Range (ATR)
- PML 0.10
- KALV 0.70
- MACD
- PML 0.01
- KALV 0.20
- Stochastic Oscillator
- PML 65.74
- KALV 61.54
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.